Novartis, Eli Lilly oppose Kerala plea to cut breast-cancer drug prices
Court filings contrast Novartis’s ₹78,400 monthly price for ribociclib with an estimated ₹5,100–₹7,750 manufacturing-based cost. The case spotlights patent-linked affordability and access pressure in India’s oncology market.
What happened
Novartis and Eli Lilly oppose a Kerala High Court petition seeking intervention to lower prices of patented breast-cancer drugs in India. Court filings contrast
Key facts
- Rs 78,400 monthly India price for Novartis's ribociclib
- Rs 5,100-Rs 7,750 estimated monthly manufacturing-based cost for ribociclib
- $12.7 billion global ribociclib sales (2020-2025)
- $55.7 million India ribociclib sales (2020-2025)
- $19.6 billion global abemaciclib sales (2020-2025)
- $31.5 million India abemaciclib sales (2020-2025)
- 0.4% India share of ribociclib global revenue
- 0.16% India share of abemaciclib global revenue
Why this matters
The dispute makes local manufacturing, voluntary licensing, and access-focused partnerships more strategically valuable for multinationals seeking to protect oncology market access in India.
What to watch
- Kerala court interim order, especially any direction for price disclosure, treatment access, or government intervention.
- Whether the Union health ministry or NPPA comments on oncology-drug affordability or signals a broader price-control review.
- New petitions targeting other patented cancer therapies or requests for compulsory licenses under Indian patent law.
- Expansion of ribociclib patient-assistance programs, government tenders, or voluntary price reductions.
- Evidence that hospitals, insurers, or state schemes restrict use of high-priced branded oncology drugs in favor of lower-cost alternatives.
- Novartis and Eli Lilly are likely to emphasize R&D costs, patent protections, existing access programs, and risks to innovation in court and public-policy engagement.
- State health authorities may seek negotiated oncology procurement discounts, patient-assistance commitments, or inclusion conditions tied to public treatment programs.
- Domestic generic manufacturers and civil-society groups may use disclosed manufacturing-cost estimates to support additional affordability petitions and compulsory-license advocacy.
- Multinational drugmakers may reassess India launch sequencing, pricing architecture, and access-program budgets for high-value oncology therapies.